Nano X Imaging Ltd (NNOX) Quote

NNOX 10Q due 4/1 per Seeking Alpha

NNOX 10Q due 3/22

Shares of several companies rallied this week after Nvidia disclosed owning stakes in them. One, Nano-X Imaging Ltd., saw its shares double over two days, adding some $400 million in market value to the medical-devices maker.

How Nvidia came to hold about $380,000 worth of its shares, though, isn’t what most investors might expect. Back in 2017, Nvidia reported a stake in Zebra Medical, an Israeli-based startup focused on using artificial intelligence to read medical images. Four years later, Nano-X acquired Zebra in an all-stock deal. That resulted in Nvidia’s receiving shares in Nano-X in return for its Zebra stake.

“The market is presuming that Nvidia consciously purchased” the stake in Nano-X, John Hempton, chief investment officer at Bronte Capital Management, wrote in a post on Substack Thursday. “Nvidia did not consciously choose to buy Nano-X stock.”

Nano-X shares lost as much as 9.5% in postmarket trading on Friday, after closing 36% higher.

The chipmaker made the disclosures in a 13-F regulatory filing, required for institutional investors whose portfolios exceed $100 million. Nvidia likely crossed that threshold at the end of last year after a company it owns a stake in, Arm Holdings Plc, went public.

Nvidia declined to comment on its Nano-X stake when contacted by Bloomberg News.
.......................................
Looks like a bottom of $5 has been put in and OBV has turned back up.
Weekly Chart

#NNOX 🔥 #NVDA great earning today! Watch $NNOX moving tomorrow!

#NNOX 🔥 can it touch $20 next week? $NNOX

Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver
Nanox’s HealthFLD is pioneering the use of a fully automated AI software for liver attenuation analysis from CT scans that has received FDA 510(k) clearance for use in general population

Expands Nanox’s offering in AI solutions, marking third product in Nanox AI’s suite of population health solutions to become commercially available

PETACH TIKVA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd., received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for HealthFLD, an artificial intelligence (AI) software that provides automated qualitative and quantitative analysis of liver attenuation from routine contrast and non-contrast chest and abdomen CT scans in patients between the ages of 18 to 75. HealthFLD is intended to support clinicians in the detection of fatty liver, correlated with hepatic steatosis, an early sign of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD).

An estimated 24% of U.S. adults are living with MASLD or NAFLDi, a metabolic disease linked to obesity, cardiovascular disease and type 2 diabetes, all of which pose significant public health concerns. Adults with MASLD are not only at risk of developing severe liver complications, such as cirrhosis and metabolic dysfunction-associated steatohepatitis (MASH), but are also at risk of cardiovascular disease, which is the leading cause of death in people living with MASLDii. MASLD is commonly asymptomatic until it progresses to advanced liver fibrosis, and the current gold standard for diagnosis is a liver biopsy, which is invasive and costly. As such, early diagnosis of MASLD could benefit patients and the healthcare system.

While AI assessment of medical imaging offers a reliable, non-invasive, large-scale approach to support clinicians in the assessment of hepatic steatosis (fatty liver), it has traditionally been difficult to assess liver attenuation on contrast-enhanced scans – which make up a large proportion of CT scans – limiting the ability of clinicians to detect non-severe cases of MASLDiii. HealthFLD was designed to help clinicians in the assessment and analysis of fatty liver in the general population from routine CT scans.

Amidst rising obesity rates, the prevalence of liver-related disease is growing, and the need for an approved treatment for MASH has yet to be met. With several late-stage drug candidates for MASH in development and the availability of GLP-1 drugs for the management of type 2 diabetes and other metabolic diseases, identification of liver steatosis is especially relevant.

"We are proud to offer HealthFLD as the third product of Nanox AI’s suite of cutting-edge, AI-powered population health solutions designed to confront chronic diseases of great public health concern head-on and potentially improve health outcomes,” said Erez Meltzer, Chief Executive Officer of Nanox. “Furthermore, we believe that AI innovative solutions, and specifically HealthFLD, may deliver substantial advantages to the biopharmaceutical industry to streamline the identification of candidates for clinical trials of much-needed therapies for liver diseases including MASH. This regulatory decision solidifies our leadership as a developer of automated AI software medical devices.”

In a retrospective 2023 study of 2,917 patients, published in the American Journal of Roentgenology (AJR), the HealthFLD AI software demonstrated high performance in the detection of at least moderate hepatic steatosis in contrast-enhanced CT scans, with a sensitivity of 77.8% and specificity of 93.2% at less than 80 HU. Medical imaging offers the only reliable noninvasive method for quantifying liver fat. Integrating HealthFLD with widely used standard CT scans offers clinicians the potential to opportunistically screen for liver steatosis and possible signs of MASLD on a population level. “In recent years, automated, deep learning tools have offered an efficient, low-cost tool used to detect diseases in earlier stages,” said Perry J. Pickhardt, MD, of the University of Wisconsin School of Medicine & Public Health, and lead author of the AJR study. “We are now at a watershed moment when metabolic diseases are growing in prevalence and more effective treatment options are becoming available. It’s promising to have a liver solution available that may help evaluate early signs of illness from routine imaging.”

The HealthFLD clearance is the third product across the Nanox AI suite of population health solutions to receive FDA clearance. The FDA previously cleared HealthCCSng, a solution that detects coronary artery calcium (CAC) that presents a risk for coronary artery disease, and HealthOST, a solution that assesses vertebral compression fractures and bone mineral density to support clinicians in the evaluation and assessment of musculoskeletal disease of the spine (such as osteoporosis).

About Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as non-alcoholic fatty liver disease (NAFLD), refers to a group of metabolic conditions linked to obesity, cardiovascular disease and type 2 diabetes. An estimated 30% of the adult population globally has MASLD,iv a major risk factor for chronic liver disease and for cardiovascular disease, which is the leading cause of mortality in this patient population.v

About Nanox AI
Nanox AI is the deep-learning medical imaging analytics subsidiary of Nanox. Nanox.AI solutions are developed to target highly prevalent chronic and acute diseases affecting large populations around the world. Leveraging AI technology, Nanox AI helps clinicians extract valuable and actionable clinical insights from routine medical imaging that otherwise may go unnoticed, potentially initiating further medical assessment to establish individual preventative care pathways for patients. For more information, please visit https://www.nanox.vision/ai.

About Nanox

Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the

NNOX: SEC Charges Diagnostic Imaging Company and its former CEO for misrepresenting the manufacturing costs of its flagship device.

https://www.sec.gov/litigation/litreleases/lr-25876

SEC Complaint:

https://www.sec.gov/files/litigation/complaints/2023/comp25876.pdf

That didn’t age very well. Let’s see if it can get over 10 LOL

nice bounce with volume near the close. Choice Choi on twitter says NNOX leased a suite in Fort Lauderdale for their US demo location

Let’s hope it bounces off of 16

The gift that keeps giving!$$$

$17

Approved by FDA on 5/3
Registered 40 million shelf shares 5/5
De-registered 40 million shelf shares 5/6
Interesting..... buyout ?

Two year later

https://www.thestreet.com/investing/advanced-imaging-firm-nano-x-makes-risky-global-move?puc=yahoo&cm_ven=YAHOO&yptr=yahoo

(shared via bit.ly/mystocksapp)

$NNOX CEO reduces stake, will leave in Jan

Today Ran has 3,278,368 shares (Consists of 2,823,389 ordinary shares & options to purchase 454,979 ordinary shares within 60 days of Sept 30 2021)

At start of 2021 Ran owned 4,806,120 shares (Shares +shares exercisable within 60 days) pic.twitter.com/s3fGbYiCmB— TerraPharma (@TerraPharma1) September 30, 2021


$NNOX CEO reduces stake, will leave in Jan

Today Ran has 3,278,368 shares (Consists of 2,823,389 ordinary shares & options to purchase 454,979 ordinary shares within 60 days of Sept 30 2021)

At start of 2021 Ran owned 4,806,120 shares (Shares +shares exercisable within 60 days)
2:18 PM · Sep 30, 2021·Twitter Web App

Looks like some gift prices here....back to $30+ soon imo.

Come to Poppa! $NNOX


"I love it when a plan comes together!"
- Colonel Hannibal Smith

Congrats to all!

Don't read the large fine print:)

LOL

* * $NNOX Video Chart 04-05-2021 * *

Link to Video - click here to watch the technical chart video

You may want to read up on FDA Approval, Clearance & Granted in regards to medical devices. This will be moving up tomorrow! https://www.greenlight.guru/blog/fda-clearance-approval-granted

Clearance is not same as approved though so I'm not sure how big of a bump will we see here in PPS next week?!

BY Reuters
— 1:18 PM ET 04/02/2021
April 2 (Reuters) - Nano-X Imaging Ltd ( NNOX


* NANOX ANNOUNCES FDA CLEARANCE OF 510(K) FOR SINGLE SOURCE NANOX.ARC DIGITAL X-RAY

* NANO-X IMAGING LTD ( NNOX
Loading...
Loading...
) - REMAINS ON TRACK AND EXPECTS TO SUBMIT A 510(K) APPLICATION TO FDA FOR ITS MULTI-SOURCE NANOX.ARC AND NANOX.CLOUD IN 2021 Source text for Eikon: Further company coverage:

Looks like I was wrong it was April 2nd!!! BOOOOM!!!

I believe FDA Clearance will be April 5th

* * $NNOX Video Chart 02-24-2021 * *

Link to Video - click here to watch the technical chart video

Lists on ARK tomorrow and FDA approval around the corner. Who’s not buying.

The technology here is not revolutionary. Careful where y’all invest your money. https://seekingalpha.com/amp/article/4393849-nano-x-vision-under-x-ray

We get some good news this month, not sure why the slide.

Nanox to Feature Nanox.ARC Digital X-Ray Technology in a Live Demonstration at the 2020 Radiology Society of North America Virtual Annual Meeting

11/25/20, 7:58 AM
NEVE ILAN, Israel, Nov. 25, 2020 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that the Company will host a live demonstration that will showcase the Nanox digital x-ray source tube and a range of 2D and 3D imaging applications performed by the Nanox.ARC at the 2020 Radiology Society of North America Virtual Annual Meeting. The live event will take place at the Nanox RSNA virtual booth on Thursday, December 3, 2020 at 11:00am E.T. An investor webinar will follow the live event on Thursday, December 3, 2020 at 2:00pm E.T.

Meetings with Investors

NNOX will be meeting with institutional investors on 3 separate days prior to their live demonstration at the end of the month. This is going to jump 3x or 4x by the beginning of December in my opinion. Definitely a long hold after proving successful scans.

They are setting themselves up to get mass production and quick turnaround to distribute these machines. Should be an exciting company to watch grow enormously.

I am interested in NNOX, and wondering if anybody have any evidence of investment from Fujifilm which is written in annual report, quarterly report, or PR of Fujifilm, not from other sources. I could not find any from Fujifilm website.

Back on watch for entry. Either $24 where it first gapped up from, or $29 where it started to run from after gapping up from $24

o crap i might need to get back out then

got 'em at 30.40

today Cramer gave his piece on the company. Demonstration in late Nov. decides stock's fate.

on Mad Money lightling round today.

* * $NNOX Video Chart 10-06-2020 * *

Link to Video - click here to watch the technical chart video

* * $NNOX Video Chart 10-05-2020 * *

Link to Video - click here to watch the technical chart video

Running 40's >

NNOX

* * $NNOX Video Chart 10-02-2020 * *

Link to Video - click here to watch the technical chart video

yeah kept on pushing to $38 but good profits in my pocket already

Congrats bud > 37.95 and running.

NNOX

Sold $35.50. Excellent ATM $$$

spread on this one is crazy yes.. that's why I don't watch it lol

$35/36 eod coming? That's my target and will reload on the pullbacks.

Out of this craziness @ 34.23 > nice ATM, but tired of bid/ask jumping all over!

33.50 > hod > nice momo

GM! NNOX sweet bs news $$$$

NNOX @ 32.44